Laverdiere M, Hoban D, Restieri C, Habel F
Department of Microbiology-Infectious Diseases, Hôpital Maisonneuve-Rosemont, 5415 Boulevard l'Assomption, Montréal, Québec H1T 2M4.
J Antimicrob Chemother. 2002 Jul;50(1):119-23. doi: 10.1093/jac/dkf074.
The in vitro activities of voriconazole, posaconazole, ravuconazole and micafungin were compared with those of fluconazole, itraconazole, ketoconazole, flucytosine and amphotericin B against 164 candidaemia isolates recovered from cancer patients in two Canadian centres. The MIC(50) results for ravuconazole, voriconazole, posaconazole and micafungin were 0.01, 0.03, 0.12 and 0.25 mg/L, respectively. The new antifungal agents showed substantial activity against isolates demonstrating in vitro resistance to fluconazole and itraconazole. These results suggest that the newer antifungal agents possess promising activity against invasive Candida isolates, particularly against those with reduced susceptibility to fluconazole and itraconazole.
在加拿大的两个中心，对伏立康唑、泊沙康唑、雷夫康唑和米卡芬净与氟康唑、伊曲康唑、酮康唑、氟胞嘧啶及两性霉素B针对从癌症患者中分离出的164株念珠菌血症菌株的体外活性进行了比较。雷夫康唑、伏立康唑、泊沙康唑和米卡芬净的MIC（50）结果分别为0.01、0.03、0.12和0.25mg/L。这些新型抗真菌药对显示出对氟康唑和伊曲康唑体外耐药的菌株具有显著活性。这些结果表明，新型抗真菌药对侵袭性念珠菌分离株具有良好的活性，尤其是对那些对氟康唑和伊曲康唑敏感性降低的菌株。
